Stockscreener 앱 받기
1.91
6.83%
-0.14
시간 외 거래:
1.91
전일 마감가:
$2.05
열려 있는:
$2.04
하루 거래량:
234.67K
Relative Volume:
0.11
시가총액:
$71.48M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.55%
1개월 성능:
-22.04%
6개월 성능:
-29.26%
1년 성능:
-82.76%
1일 변동 폭
$1.90
$2.077
1주일 범위
$1.87
$2.095
52주 변동 폭
$1.61
$11.86
Metagenomi Inc Stock (MGX) Company Profile
명칭
Metagenomi Inc
전화
(510) 871-4880
주소
5959 HORTON STREET, EMERYVILLE
MGX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
MGX
Metagenomi Inc
|
1.91 | 71.48M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
502.92 | 129.14B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.61 | 74.41B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
581.21 | 35.31B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
241.75 | 31.30B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.57 | 27.35B | 3.32B | -860.46M | -1.04B | -8.32 |
Metagenomi Inc Stock (MGX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-07 | 개시 | H.C. Wainwright | Buy |
| 2024-05-02 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-03-05 | 개시 | BMO Capital Markets | Outperform |
| 2024-03-05 | 개시 | Chardan Capital Markets | Buy |
| 2024-03-05 | 개시 | JP Morgan | Overweight |
| 2024-03-05 | 개시 | Jefferies | Buy |
| 2024-03-05 | 개시 | TD Cowen | Outperform |
| 2024-03-05 | 개시 | Wells Fargo | Overweight |
모두보기
Metagenomi Inc 주식(MGX)의 최신 뉴스
Metagenomi achieves gene integration breakthrough - Investing.com
Metagenomi Announces Publication in Nature Communications - GlobeNewswire
Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances ... - Bluefield Daily Telegraph
Metagenomi Breakthrough: New CRISPR System Enables Large Gene Integration | MGX Stock News - StockTitan
Rhumbline Advisers Increases Position in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Metagenomi, Inc. (MGX) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights - ACCESS Newswire
Metagenomi CFO Pamela Wapnick sells stock for $3,389 - Investing.com India
Metagenomi CFO Pamela Wapnick sells stock for $3,389 By Investing.com - Investing.com UK
Metagenomi, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights – MGX - ACCESS Newswire
MGX LAWSUIT ALERT: Levi & Korsinsky Notifies Metagenomi, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your RightsMGX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi LawsuitMGX - ACCESS Newswire
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of November 25, 2024 in Metagenomi, Inc. LawsuitMGX - ACCESS Newswire
Shareholders that lost money on Metagenomi, Inc.(MGX) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - ACCESS Newswire
Metagenomi, Inc. (MGX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings - ACCESS Newswire
Metagenomi advances gene editing therapies into 2025 - MSN
Shareholder Rights Advocates at Levi & Korsinsky Investigate Metagenomi, Inc. (MGX) Regarding Possible Securities Fraud Violations - ACCESS Newswire
Metagenomi, Inc. Sued for Securities Law ViolationsInvestors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your RightsMGX - ACCESS Newswire
Levi & Korsinsky Reminds Metagenomi Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - ACCESS Newswire
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Metagenomi, Inc. (NASDAQ:MGX) Receives $16.67 Average Price Target from Analysts - MarketBeat
Metagenomi, Inc. Investigated Regarding Potential Securities Law ViolationsContact Levi & Korsinsky for Details- MGX - ACCESS Newswire
A look into Metagenomi Inc (MGX)’s deeper side - SETE News
Metagenomi, Inc. (NASDAQ:MGX) Short Interest Update - MarketBeat
Levi & Korsinsky Reminds Metagenomi, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 25, 2024MGX - ACCESS Newswire
Peapod Lane Capital LLC Invests $1.27 Million in Metagenomi, Inc. (NASDAQ:MGX) - MarketBeat
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
FINAL MGX DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Metagenomi, Inc. Investors to Join the Class Action Lawsuit! - ACCESS Newswire
These two noteworthy penny stocks can do wonders! Here's more insights into Alto Ingredients, Metagenomi a - The Economic Times
Alto Ingredients And 2 Other US Penny Stocks To Watch - Simply Wall St
SG Americas Securities LLC Invests $43,000 in Metagenomi, Inc. (NASDAQ:MGX) - Defense World
Lead Plaintiff Appointed to Represent Investors in Metagenomi Class Action - TradingView
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Metagenomi to Present at TD Cowen's 45th Annual Health Care Conference - GlobeNewswire
Metagenomi Inc [MGX] Insider Activity: An Update for Investors - Knox Daily
Quarterly Metrics: Quick and Current Ratios for Metagenomi Inc (MGX) - The Dwinnex
MGX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Analysts review Metagenomi Inc’s rating - Knox Daily
Is Metagenomi Inc (MGX) worth investing in despite its overvalued state? - US Post News
MGX SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Metagenomi, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Market Watch Highlights: Metagenomi Inc (MGX) Ends on an Downturn Note at 2.69 - The Dwinnex
Neutral On Metagenomi's Promising Yet Highly Speculative Gene Editing Potential - Seeking Alpha
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer - GlobeNewswire Inc.
The Market Doesn't Like What It Sees From Metagenomi, Inc.'s (NASDAQ:MGX) Revenues Yet As Shares Tumble 26% - Simply Wall St
Brokerages Set Metagenomi, Inc. (NASDAQ:MGX) Price Target at $16.67 - MarketBeat
Investors Who Lost Money With NASDAQ:MGX Shares Should Contact the Shareholders Foundation in Connection With Lawsuit Against Metagenomi, Inc - ACCESS Newswire
Stargate Project’s healthcare winners: AI-led biotechs and Metagenomi - MSN
FINAL REMINDER MGX DEADLINE: Bronstein, Gewirtz & Grossman LLC Alerts Metagenomi, Inc. Investors to Participate in the Class Action Lawsuit! - ACCESS Newswire
StockWatch: Up-to-$500B AI Venture Sparks Investor Interest, and Questions - Genetic Engineering & Biotechnology News
Metagenomi, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights – MGX - ACCESS Newswire
Metagenomi, Inc. (NASDAQ:MGX) Given Consensus Recommendation of “Moderate Buy” by Analysts - Defense World
Metagenomi Inc (MGX) 재무 분석
Metagenomi Inc (MGX)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.39%
0.55%
자본화:
|
볼륨(24시간):